Exploring Pasithea Therapeutics Corp. (KTTA) Investor Profile: Who’s Buying and Why?

Have you ever wondered who is investing in Pasithea Therapeutics Corp. (KTTA) and why? With the stock price fluctuating, closing at $1.43 on April 21, 2025, after gaining 3.62% that day, understanding the investor landscape is more crucial than ever. While the stock has faced a significant decline of 80.94% since April 12, 2024, when it was valued at $7.45 per share, recent partnerships and regulatory clearances have sparked renewed interest. Is this a strategic move for long-term growth, or a speculative play? Let's delve into the details of KTTA's investor profile to uncover the motivations behind the investments.

Pasithea Therapeutics Corp. (KTTA) Who Invests in Pasithea Therapeutics Corp. (KTTA) and Why?

Understanding the investor profile of Pasithea Therapeutics Corp. (KTTA) involves examining the diverse range of individuals and institutions that hold its stock, as well as their motivations and strategies. This insight is crucial for current and prospective investors, offering a clearer picture of the company's shareholder base and the factors influencing its stock performance.

Pasithea Therapeutics Corp. (KTTA) attracts a mix of investor types, each with their own investment strategies and motivations:

• Retail Investors: These individual investors often focus on growth potential and are drawn to Pasithea Therapeutics Corp. (KTTA)'s work in mental health treatments.
• Institutional Investors: Investment firms, mutual funds, and pension funds analyze Pasithea Therapeutics Corp. (KTTA)'s long-term prospects.
• Hedge Funds: These funds look for short-term gains, influenced by clinical trial results and market trends.

Several factors attract investors to Pasithea Therapeutics Corp. (KTTA):

• Growth Prospects: Investors are drawn to the potential of Pasithea Therapeutics Corp. (KTTA)'s innovative treatments for mental health disorders.
• Market Position: The company's focus on unmet needs in mental health positions it favorably in a growing market.

Investors in Pasithea Therapeutics Corp. (KTTA) adopt various strategies, including:

• Long-Term Holding: Some investors maintain positions, betting on the company's long-term success.
• Short-Term Trading: Others trade based on news and market fluctuations.
• Value Investing: Some see Pasithea Therapeutics Corp. (KTTA) as undervalued, expecting future growth to boost its stock price.

For more insights into the company's direction, see Mission Statement, Vision, & Core Values of Pasithea Therapeutics Corp. (KTTA).

Pasithea Therapeutics Corp. (KTTA) Institutional Ownership and Major Shareholders of Pasithea Therapeutics Corp. (KTTA)

Understanding the institutional ownership and major shareholders of Pasithea Therapeutics Corp. (KTTA) is crucial for investors seeking insights into the company's stability, strategic direction, and potential stock performance. Institutional investors, such as hedge funds, mutual funds, and pension funds, often have a significant impact on a company's stock price due to the large volumes they trade.

As of the latest available data, information regarding the top institutional investors and their specific shareholdings in Pasithea Therapeutics Corp. (KTTA) can fluctuate. It's essential to consult the most recent regulatory filings, such as 13F filings with the Securities and Exchange Commission (SEC), to get an accurate snapshot. These filings, which institutional investment managers with over $100 million in assets under management are required to file quarterly, provide details on their equity holdings.

Changes in institutional ownership can signal shifts in sentiment towards Pasithea Therapeutics Corp. (KTTA). An increase in institutional holdings may indicate confidence in the company's future prospects, while a decrease could suggest concerns about its performance or strategy. Monitoring these changes over time can provide valuable context for investment decisions.

The role of large institutional investors in Pasithea Therapeutics Corp. (KTTA) extends beyond simply influencing the stock price. These investors often engage with company management, providing input on strategic decisions and corporate governance. Their presence can also enhance the company's credibility and attract additional investors.

To gain a comprehensive understanding of Pasithea Therapeutics Corp. (KTTA)'s investor profile, consider the following:

• Identify Top Institutional Investors: Research the largest institutional holders of KTTA shares.
• Track Ownership Changes: Monitor increases or decreases in institutional stakes through SEC filings.
• Assess Impact: Analyze how institutional ownership influences the stock price and company strategy.

Keep in mind that information on institutional ownership may not always be readily available or completely up-to-date. However, by consulting reputable financial data providers and analyzing SEC filings, investors can gain valuable insights into the ownership structure of Pasithea Therapeutics Corp. (KTTA) and its potential implications.

Pasithea Therapeutics Corp. (KTTA) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Pasithea Therapeutics Corp. (KTTA) provides critical insights into the company's stability, growth potential, and strategic direction. Examining the types of investors, their influence, and recent activities can offer a comprehensive view of market sentiment and potential future performance. As of April 2025, several key aspects define Pasithea Therapeutics' investor landscape.

Institutional ownership in Pasithea Therapeutics Corp. (KTTA) accounts for 6.09%. As of April 11, 2025, the share price was $1.42 per share, reflecting an 80.94% decline from $7.45 on April 12, 2024.

Here's a breakdown of notable investors and their influence:

• Armistice Capital, LLC: Holds a significant position among institutional investors.
• UBS Group AG: Another notable institutional holder.
• FSMAX - Fidelity Extended Market Index Fund
• Tower Research Capital LLC (TRC)
• Morgan Stanley
• FCFMX - Fidelity Series Total Market Index Fund
• Royal Bank Of Canada
• Jpmorgan Chase & Co
• Bank Of America Corp /de/

These institutions collectively hold 77,162 shares.

The presence of these major shareholders can influence company decisions through their voting rights and potential involvement in strategic discussions. Schedule 13D filings indicate investors holding more than 5% of the company who may intend to actively pursue changes in business strategy.

Recent moves by institutional investors, such as changes in their holdings, can signal shifts in confidence and expectations regarding the company's future. For instance, a significant increase in institutional ownership might suggest a positive outlook, while a decrease could indicate concerns.

Pasithea Therapeutics has 2.71 million shares outstanding, with a float of 2.46 million. Insider ownership stands at 19.08%, while institutional ownership is at 6.09%.

The ownership structure of KTTA is as follows:

• Individual Insiders: 112,859 shares, 4.17% ownership
• Institutions: 337,772 shares, 12.5% ownership
• General Public: 2,254,632 shares, 83.3% ownership

The company's market capitalization is approximately $3.8 million. The number of shares has decreased by -10.64% in one year. The enterprise value is -$3.05 million.

Here is a summary of key financial ratios:

Recent news includes Pasithea Therapeutics' presentation at the H.C. Wainwright 26th Annual Global Investment Conference in September 2024, and positive recommendations from the Safety Review Committee regarding their Phase 1 clinical trial of PAS-004 in advanced cancer.

Indian investors show growing interest in Pasithea Therapeutics (KTTA). Investment from India has increased by 1850.0% over the past 30 days, and search interest has increased by 533%.

For more insights into Pasithea Therapeutics Corp.'s mission, vision, and core values, you can visit: Mission Statement, Vision, & Core Values of Pasithea Therapeutics Corp. (KTTA).

Pasithea Therapeutics Corp. (KTTA) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Pasithea Therapeutics Corp. (KTTA) is crucial for stakeholders. This involves analyzing the attitudes of major shareholders, observing stock market responses to ownership changes, and considering analyst perspectives on the impact of key investors on the company's future.

Investor sentiment toward Pasithea Therapeutics Corp. (KTTA) can significantly influence its stock performance and overall market perception. Major shareholders' attitudes, whether positive, neutral, or negative, often reflect their confidence in the company's strategic direction and growth prospects. Monitoring these sentiments provides valuable insights into potential shifts in investment strategies and market dynamics.

Recent market reactions to changes in ownership or large investor moves offer a real-time assessment of how the market perceives these developments. Significant investments or divestments by major shareholders can trigger immediate price fluctuations, reflecting investor confidence or concern. Analyzing these reactions helps to gauge the market's short-term and long-term outlook on Pasithea Therapeutics Corp. (KTTA).

Analyst perspectives play a vital role in interpreting the impact of key investors on Pasithea Therapeutics Corp. (KTTA)'s future. Analysts often provide insights into how major investment decisions align with the company's strategic goals and potential for growth. Their analysis can influence investor sentiment by offering an informed view of the company's prospects.

Pasithea Therapeutics Corp. (KTTA) is dedicated to discovering, developing, and commercializing innovative treatments for central nervous system (CNS) disorders. You can explore more about the company's goals and values here: Mission Statement, Vision, & Core Values of Pasithea Therapeutics Corp. (KTTA).

To illustrate the kind of information that would be relevant, consider the following hypothetical scenario:

Let's imagine a hypothetical scenario for Pasithea Therapeutics Corp. (KTTA) to demonstrate the type of data that would be relevant in an analysis of investor profile and market impact. Please note that the following figures and events are purely examples for illustrative purposes.

Hypothetical Scenario:

• Major Investor Sentiment: A major institutional investor, 'XYZ Capital,' publicly expresses a positive outlook on Pasithea Therapeutics Corp. (KTTA) due to promising Phase 2 clinical trial results for its lead drug candidate in treating CNS disorders.
• Recent Market Reactions: Following XYZ Capital's announcement, KTTA's stock price jumps by 15% in a single day, accompanied by a 500% increase in trading volume compared to its average daily volume.
• Analyst Perspectives: Analysts at 'GlobalInvest Research' issue a 'Buy' rating for KTTA, setting a price target 30% higher than the current market price. They cite the potential market size for CNS disorder treatments and KTTA's strong patent portfolio as key drivers for their optimistic outlook.

Hypothetical Data Table:

This hypothetical data provides a clearer picture of how real-world information would be structured and analyzed to understand investor profiles and their impact on Pasithea Therapeutics Corp. (KTTA).